$81.63 0.0 0.0%
Last Trade - 09/02/18
| Market Cap | ÂŁn/a |
| Enterprise Value | ÂŁn/a |
| Revenue | ÂŁ119.4m |
| Position in Universe | th / 6543 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017E | 2018E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 33.9 | 40.8 | 53.8 | 69.9 | 88.6 | 109.3 | 141.5 | 230.7 | +26.4% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.
| Last Annual | December 31st, 2016 |
| Last Interim | September 30th, 2017 |
| Incorporated | March 1, 2002 |
| No. of Shareholders: | n/a |
| No. of Employees: | 501 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 44,166,579 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 20 rue Rudolph Diesel, ST-GENIS-POUILLY, 01630, France |
| Web | https://www.adacap.com/ |
| Phone | +33 4 50993070 |
| Contact | () |
| Auditors | KPMG Audit Nord |
As of 09/02/18, shares in Advanced Accelerator Applications SA are trading at $81.63, giving the company a market capitalisation of ÂŁn/a. This share price information is delayed by 15 minutes.
Shares in Advanced Accelerator Applications SA are currently trading at $81.63 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Advanced Accelerator Applications SA price has moved by -6.63% over the past year.
Of the analysts with advisory recommendations for Advanced Accelerator Applications SA, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Advanced Accelerator Applications SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Advanced Accelerator Applications SA is scheduled to issue upcoming financial results on the following dates:
Advanced Accelerator Applications SA does not currently pay a dividend.
Advanced Accelerator Applications SA does not currently pay a dividend.
Advanced Accelerator Applications SA does not currently pay a dividend.
To buy shares in Advanced Accelerator Applications SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Advanced Accelerator Applications SA are currently trading at $81.63, giving the company a market capitalisation of ÂŁn/a.
Here are the trading details for Advanced Accelerator Applications SA:
We were not able to load our ranking data for Advanced Accelerator Applications SA
We were not able to load any forecast data for Advanced Accelerator Applications SA.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Advanced Accelerator Applications SA. Over the past six months, the relative strength of its shares against the market has been -14.23%. At the current price of $81.63, shares in Advanced Accelerator Applications SA are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Advanced Accelerator Applications SA.
We were unable to find the directors for Advanced Accelerator Applications SA.
Here are the top five shareholders of Advanced Accelerator Applications SA based on the size of their shareholding:
